浙江春禾医药科技有限公司位于杭州未来科技城，公司以长期在世界大型医药公司从事新药研发的技术骨干为中坚组建，主要在帕金森疾病治疗、肿瘤治疗和各种炎症疾病治疗等领域研发具有重大医疗价值和应用前景的新型药物。
      目前，公司的第一个创新药物(VG081821)正在进行一期临床研究，并将在明年进行治疗帕金森病的二期临床研究。VG081821属于价值更高的非多巴胺类治疗帕金森病的药物(该类药物是医药界一直在追求的目标)，是首个也是目前唯一的在国内进行临床试验的该类型一类创新药物，并有望成为同类最佳药物(Best-in-class)。由于该药物属于多功能性药物，明年还计划用该药进行治疗器官纤维化的二期临床研究，之后还将用于治疗癌症等疾病的临床研究。
      与此同时，公司的第二个创新药物(VG290131)目前正在进行IND-enabling研究，并计划在明年进入一期临床试验。VG290131也属于多功能性药物，公司将首先进行治疗非酒精性脂肪肝炎(NASH)的临床试验，然后进行治疗红斑狼疮、风湿性关节炎、癌症和心肌缺血再灌注损伤等疾病的临床试验。
      另外，公司的第三和第四个创新药物的研发也在快速进展之中。根据目前的进展情况，在明年下半年，公司计划进行第三个药物(用于治疗肺炎例如新冠肺炎和肠胃炎例如溃疡性结肠炎等)的临床试验申请。
      帕金森病是一种常见的中老年疾病，不但严重影响患者的生活能力和质量，而且是继肿瘤、心脑血管病之后中老年的第三大**。目前，我国帕金森病患者约400万人，占世界帕金森病患者数量的一半以上。随着人口老龄化的加速，我国处于帕金森病患病人数急剧上升的阶段，预计每年将新增至少10万帕金森病患者。所以，治疗帕金森病的新药，尤其是由我国公司自行研发并首先在中国进行临床试验的非多巴胺类新药，对我国的帕金森病患者具有更大的意义。
      临床前试验显示，公司的VG081821还可能对老年痴呆症、精神分裂症和抑郁症等神经精神疾病起到治疗作用，并可能具有难得的神经保护和改善作用。也就是说，该药物很可能既治表、又治里，能够更好地惠及患者。
      就非酒精性脂肪肝炎来说，随着人们生活水平的广泛提高和现代工作方式的巨大变化，非酒精性脂肪肝病影响着越来越多的患者。尤其是随着肥胖和2型糖尿病患者人数的升高，非酒精性脂肪肝病的发病率已出现爆发式的增长。然而，尽管患者人数庞大，但非酒精性脂肪肝炎仍然无药可治，目前世界上还没有一个药物被批准用于非酒精性脂肪肝炎的治疗。所以，一旦研发成功，VG290131可望成为能够满足众多患者需求和为众多患者带来健康的一种药物。
      春禾医药以多做好药和增进人类的健康水平为己任，公司的目标是尽快研发出效果显著的新型药物，从而为成千上万的病人和他们的家人带来福音。
      
      
      Vimgreen Pharmaceuticals, Ltd.
      Program and Pipeline
      Summary:
      • VG081821, an A2AR antagonist, will file IND for Parkinson’s therapy next spring. o Conduct phase I trial in healthy volunteers next year. o Conduct phase II trial for PD therapy within two years. o Conduct phase II trial for cancer therapy within two years. o Conduct phase II trial for lung fibrosis within two years. • A3 agonist: Start IND-enabling study next year. o Conduct phase I trial in healthy volunteers in two years. • A2A agonist: Start IND-enabling study next year. • License-in opportunities.
      Vimgreen Pharma, founded in 2016, is a pharmaceutical company located at Hangzhou. We
      focus on the research and development of novel molecules for the treatment of cancer,
      autoimmunity and CNS diseases. Our goal is to bring innovative drugs to patients and doctors as
      early as possible, and by doing so, bring smiles to patients and their families.
      Our research programs are focused on the modulation of adenosine signaling. Adenosine is a
      major signaling molecule that is involved in a variety of critical physiological processes via activation
      of the adenosine receptors (A1, A2A, A2B or A3), including regulation of the nervous system,
      immune response, vascular function, and metabolism. In recent years, substantial progress has
      been made to understand the role of adenosine signaling in different pathologies during disease
      
      progression. These efforts have identified therapeutic possibilities for the treatment of various
      diseases, by either replenishing or inhibiting relevant adenosine signaling pathways.
      In the field of cancer immunotherapy, the adenosine signaling plays a critical role in driving
      immunosuppression in the tumor microenvironment. Here one of the most important mechanisms
      of immunosuppression is the upregulation of adenosine signaling through A2A receptors on
      immune cells. To prevent this from happening, our first program is to generate and develop a
      potent A2A antagonist for cancer immunotherapy. By using our expertise in medicinal chemistry
      and drug discovery, we have successfully developed a potent A2A antagonist — VG081821.
      VG081821 binds to A2A receptor with high affinity and selectivity. It also demonstrates high
      potency in cell-based FRET assay and FLIPR Assay. In-vitro functional studies using mouse
      splenocytes and human PBMCs demonstrate that VG081821 can fully restore the production of IL-2
      and IFN-γ. In several syngeneic mouse tumor models (MC38, A20, & B16-F10), treatment with
      VG081821 leads to significant reduction in tumor growth, both alone and in combination with anti
      PD-1 antibody. VG081821 is orally available. It possesses attractive PK properties in both mice and
      rats. The compound also displays low toxicities in vitro and in vivo. VG081821 is currently in the
      final steps of IND-enabling study, and is expected to enter clinical trials next year.
      Meanwhile, as A2A receptors and D2 receptors are co-expressed in the GABAergic
      striatopallidal neurons where adenosine and dopamine exert opposite effects in the regulation of
      locomotor activity, A2A antagonists have long been sought after as a novel non-dopaminergic
      therapy for Parkinson's disease. The recent approval of Istradefylline, an A2A antagonist, by USFDA
      is a strong testament of the new approach. Moreover, the blockade of the A2A pathway may also be
      useful for the treatment of other types of neurological disorders such as epilepsy, Huntington’s
      disease (HD), Alzheimer's disease and depression. Therefore, with VG081821, we plan to fill two
      
      needs (or more than two needs, for example, lung fibrosis) with one deed.
      Other than the A2A antagonist, we have also made substantial progress in the design and
      development of other types of modulators for the tuning of adenosine signaling. Our next IND
      enabling program (A3 agonist) is expected to start next year (2020). It has the potential for the
      treatment of both cancer and autoimmune diseases.
      The third program on the pipeline is an A2A agonist, which is aimed for autoimmune diseases.
      We plan to start the IND-enabling study next year.
      Along with the in-house drug discovery program, we have also been seeking license-in
      opportunities. Hopefully, once we have made some progress in clinical trials, it will substantially
      boost our chances in this area.
      

展开全部